AAAAAA

   
Results: 1-11 |
Results: 11
Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy
Authors: Stroup, GB Hoffman, SJ Vasko-Moser, JA Lechowska, BA Jenkins, EL Dare, LC Gowen, M
Citation: Gb. Stroup et al., Changes in bone turnover following gonadotropin-releasing hormone (GnRH) agonist administration and estrogen treatment in cynomolgus monkeys: A short-term model for evaluation of antiresorptive therapy, BONE, 28(5), 2001, pp. 532-537
Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat
Authors: Lark, MW Stroup, GB Dodds, RA Kapadia, R Hoffman, SJ Hwang, SM James, IE Lechowska, B Liang, XG Rieman, DJ Salyers, KL Ward, K Smith, BR Miller, WH Huffman, WF Gowen, M
Citation: Mw. Lark et al., Antagonism of the osteoclast vitronectin receptor with an orally active nonpeptide inhibitor prevents cancellous bone loss in the ovariectomized rat, J BONE MIN, 16(2), 2001, pp. 319-327
Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate
Authors: Stroup, GB Lark, MW Veber, DF Bhattacharyya, A Blake, S Dare, LC Erhard, KF Hoffman, SJ James, IE Marquis, RW Ru, Y Vasko-Moser, JA Smith, BR Tomaszek, T Gowen, M
Citation: Gb. Stroup et al., Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate, J BONE MIN, 16(10), 2001, pp. 1739-1746
Disease-modifying activity of SB 273005, an orally active, nonpeptide alpha(v)beta(3) (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis
Authors: Badger, AM Blake, S Kapadia, R Sarkar, S Levin, J Swift, BA Hoffman, SJ Stroup, GB Miller, WH Gowen, M Lark, MW
Citation: Am. Badger et al., Disease-modifying activity of SB 273005, an orally active, nonpeptide alpha(v)beta(3) (vitronectin receptor) antagonist, in rat adjuvant-induced arthritis, ARTH RHEUM, 44(1), 2001, pp. 128-137
Distinct mechanisms of action of selective estrogen receptor modulators inbreast and osteoblastic cells
Authors: Nuttall, ME Stroup, GB Fisher, PW Nadeau, DP Gowen, M Suva, LJ
Citation: Me. Nuttall et al., Distinct mechanisms of action of selective estrogen receptor modulators inbreast and osteoblastic cells, AM J P-CELL, 279(5), 2000, pp. C1550-C1557
Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic
Authors: Miller, WH Alberts, DP Bhatnagar, PK Bondinell, WE Callahan, JF Calvo, RR Cousins, RD Erhard, KF Heerding, DA Keenan, RM Kwon, C Manley, PJ Newlander, KA Ross, ST Samanen, JM Uzinskas, IN Venslavsky, JW Yuan, CCK Haltiwanger, RC Gowen, M Hwang, SM James, IE Lark, MW Rieman, DJ Stroup, GB Azzarano, LM Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Discovery of orally active nonpeptide vitronectin receptor antagonists based on a 2-benzazepine Gly-Asp mimetic, J MED CHEM, 43(1), 2000, pp. 22-26
Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats
Authors: Gowen, M Stroup, GB Dodds, RA James, IE Votta, BJ Smith, BR Bhatnagar, PK Lago, AM Callahan, JF DelMar, EG Miller, MA Nemeth, EF Fox, J
Citation: M. Gowen et al., Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats, J CLIN INV, 105(11), 2000, pp. 1595-1604
Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis
Authors: Badger, AM Griswold, DE Kapadia, R Blake, S Swift, BA Hoffman, SJ Stroup, GB Webb, E Rieman, DJ Gowen, M Boehm, JC Adams, JL Lee, JC
Citation: Am. Badger et al., Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis, ARTH RHEUM, 43(1), 2000, pp. 175-183
Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model
Authors: Miller, WH Bondinell, WE Cousins, RD Erhard, KF Jakas, DR Keenan, RM Ku, TW Newlander, KA Ross, ST Haltiwanger, RC Bradbeer, J Drake, FH Gowen, M Hoffman, SJ Hwang, SM James, IE Lark, MW Lechowska, B Rieman, DJ Stroup, GB Vasko-Moser, JA Zembryki, DL Azzarano, LM Adams, PC Salyers, KL Smith, BR Ward, KW Johanson, KO Huffman, WF
Citation: Wh. Miller et al., Orally bioavailable nonpeptide vitronectin receptor antagonists with efficacy in an osteoporosis model, BIOORG MED, 9(13), 1999, pp. 1807-1812
Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis
Authors: Badger, AM Blake, SM Dodds, RA Griswold, DE Swift, BA Rieman, DJ Stroup, GB Hoffman, SJ Gowen, M
Citation: Am. Badger et al., Idoxifene, a novel selective estrogen receptor modulator, is effective in a rat model of adjuvant-induced arthritis, J PHARM EXP, 291(3), 1999, pp. 1380-1386
Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis
Authors: Lark, MW Stroup, GB Hwang, SM James, IE Rieman, DJ Drake, FH Bradbeer, JN Mathur, A Erhard, KF Newlander, KA Ross, ST Salyers, KL Smith, BR Miller, WH Huffman, WF Gowen, M
Citation: Mw. Lark et al., Design and characterization of orally active Arg-Gly-Asp peptidomimetic vitronectin receptor antagonist SB 265123 for prevention of bone loss in osteoporosis, J PHARM EXP, 291(2), 1999, pp. 612-617
Risultati: 1-11 |